US pharmaceutical company Apotex Corp announced on Tuesday the launch of nilotinib capsules, a generic version of Tasigna, in the United States, with 180 days of exclusivity.

Nilotinib is a kinase inhibitor indicated to treat certain types of leukaemia, including newly diagnosed Philadelphia chromosome positive chronic myeloid leukaemia (Ph+ CML) in chronic phase in adults and children aged 1 year and older. It is also indicated for adults and paediatric patients with chronic or accelerated phase Ph+ CML with resistance or intolerance to prior therapy, demonstrating higher efficacy compared with other available treatments.

"The launch of nilotinib highlights our commitment to providing affordable, high-quality, critical medications to patients in need," said Christine Baeder, president, Apotex USA. "By offering the first generic version of this important leukaemia treatment, we improve access and outcomes for both adult and paediatric patients facing this serious disease."